Herlev

• Double-Blind, Randomized, Placebo-Controlled, Phase 1b, Pharmacodynamic Trial of TEV-56192 Following a Single Intravenous Administration in … Ended
  2023-507018-29-00 3 2024-03-05 Pruritus
• A study to learn how well the study treatment finerenone works and how safe it is in people with long-term decrease in the kidneys’ ability … Ended
  2022-503024-27-00 5 2024-02-27 Chronic kidney disease associated with type 1 diabetes mellitus
• A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended
  2022-502461-23-00 5 2024-02-15 Prurigo Nodularis
• Orismilast for the treatment of moderate to severe ulcerative colitis Ended
  2022-502763-37-02 4 2023-11-16 ulcerative colitis
• REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight … Ended
  2022-502678-18-00 5 2023-11-07 Type 2 diabetes
• Study of efficacy and safety of secukinumab in participants with moderate-severe rotator cuff tendinopathy Ended
  2022-502080-38-00 5 2023-10-16 Moderate to severe rotator cuff tendinopathy
• Orchid 1 Ended
  2023-503516-32-00 4 2023-10-12 Vulvar lichen sclerosus (VLS)
• Effects of empagliflozin on plasma glucose in patients with HNF1A-MODY: a randomized, double-blind, crossover trial Ended
  2023-503760-17-00 4 2023-10-11 Maturity-onset diabetes of the young type 3 (HNF1A-MODY)
• Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors Ended
  2022-502787-20-00 4 2023-09-28 Melanoma and squamous cell carcinoma of the head and neck
• A randomized, placebo controlled, investigator and participant-blinded study, investigating safety, tolerability and efficacy of RHH646 in p … Ended
  2022-502821-16-00 4 2023-09-01 Knee Osteoarthritis
• Efficacy of Remimazolam with Fentanyl versus Midazolam with Fentanyl Ended
  2023-503470-21-00 6 2023-08-25 Screening patients
• The RADIAL study: A clinical trial to learn more about the benefits and the acceptability of trials that include technology to centre the tr … Ended
  2022-500449-26-00 6 2023-08-03 Type 2 diabetes mellitus (T2DM)
• Ecopipam Tablets to Study Tourette’s Disorder in Children, Adolescents and Adults (D1AMOND) Ended
  2023-503494-38-00 5 2023-07-20 Tourette’s Disorder
• Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended
  2023-506046-24-00 4 2023-07-03 Ulcerative Colitis (UC)
• Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer (CheckVAC) Ended
  2024-515966-14-00 1 2023-05-03 advanced pancreatic cancer
• Oral antibiotics to prevent infection and wound dehiscence after obstetric perineal tear Ended
  2022-501930-49-00 6 2023-03-21 Obstetric perineal ruptur
• A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)] Ended
  2022-501426-38-00 4 2023-02-09 Lipoprotein Disorder
• A proof-of-concept study to examine QUC398 in participants with knee osteoarthritis Ended
  2023-509274-28-00 4 2023-02-03 Knee osteoarthritis
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• A Study of MK-1088 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors Ended
  2022-502288-40-00 4 2022-06-29 Treatment of advanced/metastatic solid tumors
• A study to learn how well the treatment combination of finerenone and empagliflozin works and how safe it is compared to each treatment alon … Ended
  2023-506981-30-00 4 2022-05-25 Chronic kidney disease in type 2 diabetes mellitus
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended
  2024-511996-13-00 5 2022-05-11 Previously untreated, unresectable, or metastatic melanoma
• Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis Ended
  2023-506004-93-00 4 2022-03-01 Ulcerative Colitis (UC)

Showing 241–264 of 293 trials